728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Perlmutter Cancer Center Expands Clinical Leukemia Program

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

NEW YORK, Nov. 29, 2017 /PRNewswire-USNewswire/ — NYU Langone Health has announced that nationally renowned physician and researcher Raoul Tibes, MD, PhD, will lead efforts to expand the clinical and investigative leukemia programs at its Perlmutter Cancer Center.

With a notable career in hematology that synergistically crosses between clinical care and laboratory research, Dr. Tibes joins Perlmutter Cancer Center from Mayo Clinic in Scottsdale and Phoenix, where he served as an assistant professor of medicine and a clinical consultant to Mayo Clinic’s Arizona-based facilities.

Dr. Raoul Tibes

Dr. Tibes’s research focuses on developing more effective therapies for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), as well on identifying mechanisms of resistance to current therapies for these diseases. His clinical trials and laboratory work led to the development of the first-of-its-kind smoothened (SMO)/Hedgehog pathway inhibitor, a pathway that is altered by mutations in certain types of cancer. He was closely involved in the first trials demonstrating the activity of SMO inhibitors in basal cell carcinomas, which ultimately led to U.S. Food and Drug Administration approval of this drug class. He has since extended his research to focus on SMO/Hedgehog pathway inhibitors in myeloid malignancies, as well as the DNA damage response in leukemia therapy.

“Dr. Tibes has a unique expertise and perspective, as both a clinician and a researcher, to lead the clinical application of genomic discoveries and advances in targeted therapies for blood cancer,” says Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center. “Under his leadership, we will improve the care and quality of life for patients by moving preclinical results and novel therapeutic combinations more rapidly into the clinic. Raoul will develop investigator-initiated trials along with specific biomarkers for blood cancers like leukemia. He will also work closely with Samer-Al Homsi, MD, our recently arrived director of bone marrow transplantation.”

About Dr. Tibes

Dr. Tibes received his medical degree and doctorate from Ludwig Maximilians University Medical School in Munich. He completed his internship and residency at NYU School of Medicine and a fellowship in medical oncology and hematology at MD Anderson Cancer Center in Houston. Before joining Mayo Clinic in 2010, he held academic and research positions at the Translational Genomics Research Institute in Phoenix, the Scottsdale Clinical Research Institute at Virginia Piper Cancer Center,

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *